Drug Formulary information is intended for use by healthcare professionals. It is not intended to be medical advice. Some of the information, including information about funding for cancer drugs, does not apply to all patients. Cancer treatment plans are unique to each patient. If you are a patient, please speak with your healthcare team to understand how this information applies to you.
Severe weather warning in your area. Please stay indoors and stay safe. Read more
regimen
DARADEXALENA(SC)
- Cancer Type
- Hematologic, Multiple Myeloma
- Intent
-
Palliative
- Regimen Category
-
Evidence-Informed
- Funding Program
-
New Drug Funding Program Daratumumab - In Combination with Lenalidomide and Dexamethasone for Relapsed Multiple Myeloma ODB - General Benefit dexamethasone ODB Limited Use lenalidomide - For the treatment of patients with multiple myeloma, who are deemed to be lenalidomide sensitive, and/or have not experienced progression while on a lenalidomide-based regimen in the treatment or maintenance setting, according to specific criteria
- Drugs Used
- daratumumab (subcut) , dexamethasone , lenalidomide
Regimen Monograph
Apr 2026
Patient Info Sheet
Please see Drugs Used for related Patient Information Sheets. Patient Information Sheets are not yet available for this regimen.
Last Updated: July 21, 2026
